Noninvasive detection of IDH mutations in gliomas using MRI
Official title: Magnetic Resonance Spectroscopy Markers of Glioma Genomics
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT05700071 · Data updated 2026-11-12
This study is trying to see if a special MRI can help find IDH mutations in brain tumors called gliomas to better guide treatment for patients with these tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 2 sites (Paris and 1 other locations) |
| Status | Recruiting |
| Started | March 6, 2023 |
| Main results expected | December 31, 2027 |
| Study ends | March 2, 2028 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT05700071 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with probable or confirmed grade II/III gliomas who are scheduled for surgery or have not received prior treatment.
✕Probably not a fit
Patients with contraindications to MRI or those with gliomas that do not exhibit IDH mutations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial focuses on the noninvasive detection of isocitrate dehydrogenase (IDH) mutations in gliomas through 1H magnetic resonance spectroscopy (MRS). It aims to identify the accumulation of D-2-hydroxyglutarate (2HG), a biomarker associated with IDH-mutated gliomas, which can aid in patient management and treatment decisions. The study will include patients with either probable or histologically confirmed low-grade gliomas, assessing their eligibility based on specific criteria. The trial is conducted at Hôpital Pitié Salpêtrière in Paris, France.
Why it matters
Potential benefit: If successful, this approach could provide a noninvasive method for diagnosing and monitoring gliomas, leading to improved patient outcomes.
How similar studies have gone: Other studies have shown promise in using MRS for detecting metabolic changes in gliomas, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : * Affiliations to a social security scheme (as a beneficiary or a person entitled to benefits) * Obtainig written, informed consent * One of the following two situations * Group 1 : Probable grade II/III/IV glioma, for which excision is scheduled. * Group 2 : Histologically confirmed grade II or III glioma with known IDH1/IDH2 status, which has received no treatment other than surgery and is due to undergo therapy other than surgery. * Presence of measurable tumor residue (\>2 cm in diameter on FLAIR imaging) * Karnofsky Index \> 60 * Effective contraception throughout the study, supplemented by a negative pregnancy test for women of childbearing age. Exclusion Criteria: • Containdications to MRI : Pacemaker or neural stimulators, intraocular or intracerebral metallic foreign bodies, cochlear implant, heart valve or metallic surgical arterial devices that are not MRI ompatible, metallic devices susceptible to concentrating radio-frequency pulses, claustrophobia * Pregnant or breastfeeding women * Regulatory criteria : Pregnant women, women in labor, breastfeeding women ; Failure to sign the consent form or paticipant refusal ; Legal protection measures (guardianship, curatorship, judicial protection) ; Participation in another research study that does not allow for compliance with the exclusion period between the two studies ; Individuals not covered by a health insurance scheme.
Where it's running
-
Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris
Paris, Île-de-France Region, France Recruiting -
Pitié-Salpetrière Hospital
Paris, France Not yet recruiting
Study contacts
- Principal investigator: Marc Sanson, MD, PhD — Paris Brain Institute, AP-HP, Paris, France
- Study coordinator: Marc Sanson, MD, PhD
- Email: marc.sanson@aphp.fr
- Phone: (0)1 42 16 03 91
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.